drugset
Drugs / PSA/IL-2/GM-CSF
last change Dec 2018 re-read 3 minutes ago

PSA/IL-2/GM-CSF

Vaccine

Developed for
prostate cancer
Investigated by
OncBioMune Pharmaceuticals · United States Department of Defense

Trials 1

today NCT02058680 · Ph 1
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02058680 Apr 2012 → Dec 2018 prostate cancer OncBioMune Pharmaceuticals Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PSA/IL-2/GM-CSF ClinicalTrials.gov intervention name — accepted as the source's own label NCT02058680 ↗
Modality Vaccine “PSA/IL-2/GM-CSF vaccine” NCT02058680 ↗